Abstract evaluation of the treatment outcomes of late-stage gastric cancer using TCX regimen at Hanoi Oncology Hospital from 2016 to 2019

https://doi.org/10.52322/jocmbmh.120.15

Abstract

Introduction: In recent years, Hanoi Oncology Hospital has introduced the modified DCF regimen (mDCF) and Paclitaxel regimen in combination with Platinum and 5 FU with dose adjustment (TCX) to be applied for the first-line treatment of late-stage gastric cancer. 

Objectives: To evaluate treatment outcomes of late gastric cancer with TCX regimen at Hanoi Oncology Hospital from 2016 to 2019. Material and Methods: An uncontrolled clinical intervention study on 71 patients with late-stage gastric cancer who were treated with TCX chemotherapy at Hanoi Oncology Hospital from January 2016 to the end of December 2019. Treatment outcomes were assessed by the performance status (PS), progression-free survival and overall survival after 6 months, 1 year and 2 years after treatment. 

Results: 4 patients had PS = 0 before treatment and increased to 7 patients after treatment. The proportion of patients had PS = 1 before treatment increased to 46 patients after treatment, 21 patients had PS = 2 before treatment, and decreased to 14 patients after treatment. There were 3 patients with PS = 3 after treatment. The overall response rate was 53.5%; in which complete response accounted for 2.8%. The disease was stable in 28.2% of cases and progressed in 18.3% of patients. The mean progression-free survival was 10.3 ± 7.4 months and overall survival was 16.1 ± 6.8 months. 

Conclusion: TCX regimen showed good outcomes in treating for patients with late-stage gastric cancer at Hanoi Oncology Hospital.